<DOC>
	<DOCNO>NCT02526524</DOCNO>
	<brief_summary>The purpose study compare glycemic effect delayed-release metformin ( Met DR ) placebo subject type 2 diabetes mellitus ( T2DM ) 16 week . The study design evaluate several dos Met DR ( 600 1500 mg daily morning [ qAM ] ) compare placebo . A single-blind reference treatment 2000 mg metformin immediate-release ( Met IR ) per day administer equal divide dos ( 1000 mg Met IR BID ) also include .</brief_summary>
	<brief_title>Dose-Ranging Study Evaluate Glycemic Effects , Safety , Tolerability Metformin Delayed Release Subjects With T2DM</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Is least 25 year old Visit 1 ( Screening ) . 2 . Is male , female meet follow criterion : 1 . Not breastfeed 2 . Negative pregnancy test result Visit 1 ( applicable postmenopausal surgically sterile female ) 3 . Surgically sterile , postmenopausal , childbearing potential , must practice willing continue practice appropriate birth control entire duration study . 3 . Body mass index ( BMI ) 20.0 45.0 kg/m² ( inclusive ) Visit 1 ( Screening ) . 4 . Has physical examination clinically significant abnormality judge investigator . 5 . Has T2DM HbA1c 7.5 % 10.5 % , inclusive , Visit 1 . 6 . Has estimate glomerular filtration rate ( eGFR ) value ≥60 mL/min/1.73 m² base Modification Diet Renal Disease ( MDRD ) equation . 7 . Either treat stable treatment regimen follow medication minimum 3 month prior Visit 1 : 1 . Thiazolidinedione , sulfonylurea , dipeptidyl peptidase4 inhibitor , alphaglucosidase inhibitor 2 . Hormone replacement therapy ( female subject ) testosterone ( male subject ) 3 . Oral contraceptive ( female subject ) 4 . Antihypertensive agent 5 . Lipidlowering agent 6 . Thyroid replacement therapy 7 . Antidepressant agent 8 . Ability understand willingness adhere protocol requirement . 1 . Has clinically significant medical condition judge investigator could potentially affect study participation and/or personal wellbeing , include limited following condition : 1 . Hepatic disease 2 . Gastrointestinal disease 3 . Endocrine disorder ( T2DM allow ) 4 . Cardiovascular disease 5 . Central nervous system diseases 6 . Psychiatric neurological disorder 7 . Organ transplantation 8 . Chronic acute infection 9 . Orthostatic hypotension , faint spell blackouts 10 . Allergy hypersensitivity . 2 . A history diabetic ketoacidosis hyperosmolar nonketotic hyperglycemia within past year . 3 . Prior major surgery kind within 6 month Visit 1 . 4 . A history &gt; 3 % weight change within 3 month Visit 1 . 5 . A clinical laboratory test ( clinical chemistry , hematology , urinalysis ) abnormality , related T2DM , judge investigator clinically significant Visit 1 . 6 . An alanine aminotransferase aspartate aminotransferase result &gt; 2.5 × upper limit normal ( ULN ) bilirubin result &gt; 1.5 × ULN . 7 . A physical , psychological , historical finding , investigator 's opinion , would make subject unsuitable study . 8 . Has treat , currently treat , expect require undergo treatment follow excluded medication : 1 . Metformin within 2 month Visit 1 ( Screening ) 2 . Insulin within 2 week Visit 1 ( Screening ) 1 week within 3 month Visit 1 ( Screening ) 3 . Glucagonlike peptide1 receptor agonist sodiumglucose cotransporter 2 inhibitor within 3 month Visit 1 4 . Drugs know affect body weight , include prescription medication overthecounter anti obesity agent within 3 month Visit 1 . 5 . Systemic corticosteroid oral , intravenous , intramuscular route ; potent , inhale , intrapulmonary steroid know high rate systemic absorption within 3 month Visit 1 6 . Planned use drug treatment affect gastric pH ( prescription overthecounter ) , H2receptor antagonists proton pump inhibitor , Visit 2 ( Week 2 ) , plan chronic use antacid ( i.e. , twice per week ) Visit 2 ( Week 2 ) 7 . Cationic drug eliminate renal tubular secretion within 1 week Visit 1 . 8 . Iodinated contrast dye within 1 week prior Visit 1 . 9 . Investigational drug within 2 month ( five halflives investigational drug , whichever great ) date first dose randomize study medication . 10 . Met DR doubleblind match placebo Met DR time prior Visit 1 ( Screening ) 9 . Currently abuse drug alcohol history abuse investigator 's opinion would cause individual noncompliant study procedure . 10 . Had blood transfusion experience significant blood loss ( i.e. , &gt; 500 mL ) , include loss due blood donation , within 2 month prior Visit 1 ( Screening ) , plan donate blood study . 11 . Has know immune system base allergy hypersensitivity component study treatment . A history gastrointestinal intolerance metformin exclusionary . 12 . Is employed Elcelyx Therapeutics , Inc. ( employee , contract worker , designee company ) . 13 . Has fast plasma glucose value &gt; 270 mg/dL Visit 1 ( Screening ) , Visit 2 ( Week 2 ) , unscheduled visit complete within 1 week follow Visit 2 . The unscheduled visit complete subject fast plasma glucose value &gt; 270 mg/dL Visit 1 Visit 2 .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>